Analyst: ”A great day for Novo”
Novo Nordisk published new solid phase III data from two of the company’s blockbuster prospects in the space of one hour on Tuesday.
BY LOUISE WENDT JENSEN
“It’s two very strong hands to play in the space of an hour,” says Sydbank’s senior analyst Søren Løntoft Hansen in response to Novo Nordisk’s publication of data from separate phase III studies with two of the company’s core assets.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
